Overview

* LifeStance Q3 revenue grows 16% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q3 beats estimates, reflecting improved operational efficiency

* Company reports net income of $1.1 mln, a turnaround from prior-year loss

Outlook

* LifeStance reiterates full-year revenue guidance of $1.41 bln to $1.43 bln

* Company raises full-year Adjusted EBITDA expectations to $146 mln to $152 mln

* LifeStance expects Q4 revenue between $368 mln and $388 mln

Result Drivers

* VISIT VOLUMES - 17% increase in visit volumes driven by clinician growth and productivity improvements

* CLINICIAN EXPANSION - Clinician base grew 11% to 7,996, aiding in revenue and visit volume increases

* OPERATING LEVERAGE - Improved operating leverage from revenue outpacing G&A expenses, boosting Adjusted EBITDA

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $363.80 $355.60

Revenue mln mln (7

Analysts

)

Q3 Net $1.10

Income mln

Q3 Beat $40.20 $35.16

Adjusted mln mln (7

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for LifeStance Health Group Inc ( LFST ) is $8.25, about 41.7% above its November 5 closing price of $4.81

* The stock recently traded at 121 times the next 12-month earnings vs. a P/E of 1,965 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)